Published in JAMA Dermatology
This extension study of 2 randomized clinical trials examines the continuous use of baricitinib in patients with atopic dermatitis from the originating studies to 68 weeks of treatment.
Published in JAMA Dermatology
This population-based cohort study examined whether a childhood diagnosis of atopic dermatitis is associated with lower educational attainment among children in Denmark.
Published in JAMA Dermatology
Importance Prospective data are limited on pregnancy outcomes among women with psoriasis who may be receiving biologic or conventional systemic therapy. Objective To report pregnancy outcomes observed in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Design, Setting, and Participants This cohort study used data from PSOLAR, a multicen...
Published in JAMA Dermatology
Importance Treatments for psoriasis may be less effective in everyday practice than in clinical trials. Emulating a target trial using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) can provide treatment effect estimates that are robust and can inform both clinicians and regulatory bodies. Objec...
Published in JAMA dermatology
Although palmoplantar pustulosis (PPP) can significantly impact quality of life, the factors underlying disease severity have not been studied. To examine the factors associated with PPP severity. An observational, cross-sectional study of 2 cohorts was conducted. A UK data set including 203 patients was obtained through the Anakinra in Pustular Ps...
Published in JAMA Dermatology
Importance Demonstrating the value of therapies from a patient’s perspective is increasingly important for patient-centered care. Objective To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life (HRQL), and mental health among patients with moderate to severe ps...
Published in JAMA dermatology
Up to 90% of patients treated with an epidermal growth factor receptor inhibitor (EGFRi) experience cutaneous toxic effects that are negatively associated with quality of life and lead to treatment interruptions. The Skin Toxicity Evaluation Protocol With Panitumumab trial found reduced incidence of skin toxicity and quality of life impairment with...
Published in JAMA dermatology
Acne is a common dermatologic condition and significantly affects psychosocial health and quality of life. An international task force recommended routine use of quality-of-life measures for clinic visits associated with acne management, but this has yet to translate into clinical practice. To assess mean Skindex-16 scores over time among patients ...
Published in JAMA dermatology
Associations between atopic eczema and cancer are unclear, with competing theories that increased immune surveillance decreases cancer risk and that immune stimulation increases cancer risk. Establishing baseline cancer risk in people with atopic eczema is important before exploring the association between new biologic drugs for atopic eczema and c...
Published in JAMA Dermatology
Importance Approximately one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths annually. Methotrexate, cyclosporine, and tumor necrosis factor inhibitors may be associated with increased risk of TB and LTBI reactivation, although data are limited on the ...
